Tassos Georgiadis
Senior Vice President Discovery & Preclinical Development MeiraGTx
Tassos has been working on retinal gene therapy for 25 years. He has developed AAV vectors for a range of indications that are currently in clinical development (Ph1/2, Ph3, pre-commercialization). He is currently Senior Vice President, Discovery & Preclinical Development at MeiraGTx establishing a multi-platform assessment strategy for drug product candidate screening, with a focus on retina and CNS.
Seminars
Wednesday 25th March 2026
Improving Probability of Success Through Multiple Platform Testing
12:00 pm
- Animal vs human-derived platforms for gene therapy efficacy and relevance
- Vector genome element screening: Plasmid or AAV?
- What’s your true titre/dose? Dose extrapolation – the ocular story
